Global Hepatocyte Growth Factors Market Size Study, by Type (Phase III, Phase II, Phase II, Phase I, Preclinical) by Application by End-User and Regional Forecasts 2022-2032

PUBLISHED: August 20, 2024

PAGES: 285 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global Hepatocyte Growth Factors (HGFs) market is valued at approximately USD 70.3 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2024-2032. Hepatocyte Growth Factors (HGFs) are potent mitogens for hepatocytes and various other cells including keratinocytes, melanocytes, epithelial, and endothelial cells. HGFs act as ligands for receptors encoded by the c-met proto-oncogene. The growth factors are crucial for diverse applications such as bioprocessing, cell culture, and regenerative medicine. These factors stimulate and regulate cellular activities, ensuring the viability and optimal growth of cells used in biopharmaceutical production. Producing high-quality recombinant growth factors is expensive, limiting their accessibility. Additionally, the short shelf life poses challenges in transportation, storage, and product viability, which may restrain the industry. However, the market is set to grow due to an exponential rise in liver illnesses and the increasing number of surgical operations that necessitate the use of HGFs for efficient and speedy wound healing.

Companies in the hepatocyte growth factors market are expanding their reach to unexplored economies in Asia Pacific, Latin America, and the Middle East & Africa to create awareness about these growth factors and prevent complications from inappropriately managed post-surgical operations.

Hepatocyte Growth Factor (HGF) is essential for liver regeneration as it promotes the growth of liver stem cells through signaling pathways that facilitate hepatic tissue healing, including collagen deposition. This process creates an environment conducive to the growth and expansion of progenitor cells. The International Journal of Pharmaceutical Chemistry and Analysis attributes 4% of global fatalities to liver disease, highlighting the critical need for proper healing of liver illnesses, thereby catalyzing the HGF market. Hepatocyte growth factor (HGF) regulates cell growth, morphogenesis, and cell motility in various cells, promoting neovascularization and epithelial repair during wound healing. HGFs act as hormone-like molecules that interact with exclusive cell surface receptors to control tissue repair. Despite being present in nanograms, they significantly influence wound repair and healing. With over 310 million major surgeries performed annually, according to the National Institutes of Health, HGFs are vital for post-surgical wound healing, expanding the market size.

North America dominated the hepatocyte growth factors market in 2023 and is expected to maintain its dominance during the forecast period, attributed to significant R&D investments by pharmaceutical companies, biotech firms, and research institutions in the U.S. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period. Asia Pacific's notable market growth is driven by Japan's advanced healthcare infrastructure and matured biopharmaceutical industry, along with extensive R&D in China.

Major market players included in this report are:

AVEO Pharmaceuticals, Inc.
Molecular Partners AG
YooYoung Pharmaceutical Co., Ltd.
F-star Therapeutics Inc.
Galaxy Bio Tech
Kringle Pharma
Novo Nordisk
Bristol-Myers Squibb
AstraZeneca
Merck & Co., Inc.
Gilead Sciences, Inc.
Sanofi SE
ViroMed
AnGes, Inc.
M3 Biotechnology, Inc.

The detailed segments and sub-segment of the market are explained below:

By Type:

Phase III (Ongoing)
Phase II (Approved)
Phase II (Ongoing)
Phase I
Preclinical

By Application:

Oncology
Cardiovascular
Central Nervous System
Hematological Disorders

By End-User:

Pharmaceutical and Biotechnology Companies
CMOs & CDMOs
Research Centers & Academic Institutes

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Hepatocyte Growth Factors (HGFs) Market Executive Summary

1.1. Global Hepatocyte Growth Factors (HGFs) Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Application
- 1.3.3. By End-User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Hepatocyte Growth Factors (HGFs) Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Hepatocyte Growth Factors (HGFs) Market Dynamics

3.1. Market Drivers
- 3.1.1. Rise in Incidence of Liver Illnesses
- 3.1.2. Increase in Surgical Operations
3.2. Market Challenges
- 3.2.1. High Cost and Limited Accessibility
- 3.2.2. Short Shelf Life and Storage Issues
3.3. Market Opportunities
- 3.3.1. Expanding Awareness in Emerging Markets
- 3.3.2. Advances in Biotechnology and Regenerative Medicine

Chapter 4. Global Hepatocyte Growth Factors (HGFs) Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Hepatocyte Growth Factors (HGFs) Market Size & Forecasts by Type 2022-2032

5.1. Segment Dashboard
5.2. Global Hepatocyte Growth Factors (HGFs) Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 5.2.1. Phase III (Ongoing)
- 5.2.2. Phase II (Approved)
- 5.2.3. Phase II (Ongoing)
- 5.2.4. Phase I
- 5.2.5. Preclinical

Chapter 6. Global Hepatocyte Growth Factors (HGFs) Market Size & Forecasts by Application 2022-2032

6.1. Segment Dashboard
6.2. Global Hepatocyte Growth Factors (HGFs) Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 6.2.1. Oncology
- 6.2.2. Cardiovascular
- 6.2.3. Central Nervous System
- 6.2.4. Hematological Disorders

Chapter 7. Global Hepatocyte Growth Factors (HGFs) Market Size & Forecasts by End-User 2022-2032

7.1. Segment Dashboard
7.2. Global Hepatocyte Growth Factors (HGFs) Market: End-User Revenue Trend Analysis, 2022 & 2032 (USD Million)
- 7.2.1. Pharmaceutical and Biotechnology Companies
- 7.2.2. CMOs & CDMOs
- 7.2.3. Research Centers & Academic Institutes

Chapter 8. Global Hepatocyte Growth Factors (HGFs) Market Size & Forecasts by Region 2022-2032

8.1. North America Hepatocyte Growth Factors (HGFs) Market
- 8.1.1. U.S. Hepatocyte Growth Factors (HGFs) Market
  - 8.1.1.1. Type breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Application breakdown size & forecasts, 2022-2032
  - 8.1.1.3. End-User breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Hepatocyte Growth Factors (HGFs) Market
8.2. Europe Hepatocyte Growth Factors (HGFs) Market
- 8.2.1. U.K. Hepatocyte Growth Factors (HGFs) Market
- 8.2.2. Germany Hepatocyte Growth Factors (HGFs) Market
- 8.2.3. France Hepatocyte Growth Factors (HGFs) Market
- 8.2.4. Spain Hepatocyte Growth Factors (HGFs) Market
- 8.2.5. Italy Hepatocyte Growth Factors (HGFs) Market
- 8.2.6. Rest of Europe Hepatocyte Growth Factors (HGFs) Market
8.3. Asia-Pacific Hepatocyte Growth Factors (HGFs) Market
- 8.3.1. China Hepatocyte Growth Factors (HGFs) Market
- 8.3.2. India Hepatocyte Growth Factors (HGFs) Market
- 8.3.3. Japan Hepatocyte Growth Factors (HGFs) Market
- 8.3.4. Australia Hepatocyte Growth Factors (HGFs) Market
- 8.3.5. South Korea Hepatocyte Growth Factors (HGFs) Market
- 8.3.6. Rest of Asia Pacific Hepatocyte Growth Factors (HGFs) Market
8.4. Latin America Hepatocyte Growth Factors (HGFs) Market
- 8.4.1. Brazil Hepatocyte Growth Factors (HGFs) Market
- 8.4.2. Mexico Hepatocyte Growth Factors (HGFs) Market
- 8.4.3. Rest of Latin America Hepatocyte Growth Factors (HGFs) Market
8.5. Middle East & Africa Hepatocyte Growth Factors (HGFs) Market
- 8.5.1. Saudi Arabia Hepatocyte Growth Factors (HGFs) Market
- 8.5.2. South Africa Hepatocyte Growth Factors (HGFs) Market
- 8.5.3. Rest of Middle East & Africa Hepatocyte Growth Factors (HGFs) Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. AVEO Pharmaceuticals, Inc.
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Molecular Partners AG
- 9.3.3. YooYoung Pharmaceutical Co., Ltd.
- 9.3.4. F-star Therapeutics Inc.
- 9.3.5. Galaxy Bio Tech
- 9.3.6. Kringle Pharma
- 9.3.7. Novo Nordisk
- 9.3.8. Bristol-Myers Squibb
- 9.3.9. AstraZeneca
- 9.3.10. Merck & Co., Inc.
- 9.3.11. Gilead Sciences, Inc.
- 9.3.12. Sanofi
- 9.3.13. ViroMed
- 9.3.14. AnGes, Inc.
- 9.3.15. M3 Biotechnology, Inc.

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes